HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains $35 price target.
Janux Therapeutics Q4 EPS $(0.39) Beats $(0.49) Estimate, Sales $2.85M Beat $790.00K Estimate
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.49) by 20.41 percent. This is a 18.18 percent decrease over losses of $(0.33) per share
William Blair Initiates Coverage On Janux Therapeutics with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session.
Zendesk, Quotient, + 40 Stocks Moving In Friday’s Mid-Day Session
Gainers
USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Looking Into Janux Therapeutics’s Return On Capital Employed
According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41 million.
